Nav: Home

ASCO: Finally, a tool to predict response to chemotherapy before bladder cancer surgery

May 31, 2019

University of Colorado Cancer Center led clinical trial data show that a predictive tool called COXEN may show which bladder cancer patients will respond to pre-surgical chemotherapy, a step towards allowing doctors to offer such chemotherapy to patients likely to respond, while moving more efficiently to other treatment options with patients unlikely to benefit. Results will be presented Monday, June 3 at 8:00am as oral abstract at the 2019 American Society for Clinical Oncology (ASCO) Annual Meeting (ASCO abstract #4506).

"The idea is that for any individual tumor, its gene expression could tell us whether the cancer will respond to a certain kind of chemotherapy," says Thomas Flaig, MD, Associate Dean for Clinical Research at University of Colorado School of Medicine, Chief Clinical Research Officer of UCHealth, and national principal investigator of the COXEN phase II clinical trial. "This is an important clinical application of a concept developed by investigators based in Colorado, which may have implications in predicting the response to chemotherapies across many cancer types."

COXEN, which stands for co-expression gene analysis, was pioneered by former CU Cancer Center Director, Dan Theodorescu, MD, PhD, now director of the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai. Thoedorescu's lab used 60 human-derived cancer cell lines curated by the National Cancer Institute to develop a gene expression approach to predicting the sensitivity of these cells to various chemotherapies. The COXEN principle was operationalized for use in the current clinical trial by Dan Gustafson, PhD, CU Cancer Center investigator and research director at Colorado State University Flint Animal Cancer Center.

"Gustafson is very good at math and translating it into the clinical setting," Flaig says. "He was critical to getting this trial up and running."

The trial enrolled 237 patients with locally advanced bladder cancer, who, as per standard of care, would receive pre-surgical (neo-adjuvant) chemotherapy meant to shrink the cancer and eradicate any microscopic deposits outside of the bladder to increase patients' overall survival. The challenge for patients and doctors has been that there are two approved chemotherapy regimens for this indication - Gemcitabine-Cisplatin (GC) and Methotrexate-Vinblastine-Adriamycin/doxorubicin-Cisplatin (MVAC).

"It's really been a coin-flip between the two," says Flaig.

Then, once patients start GC or MVAC, most but not all will respond, and there has been no way to predict which patients will benefit. Patients who do respond to GC or MVAC have a higher chance of curative surgery; patients who do not respond to GC or MVAC have wasted precious time during which their cancer can, in fact, grow prior to surgery, making a successful surgery much less likely.

"If they do respond, you've increased your cure rate. If patients don't respond, you've delayed surgery. The problem is that clinicians are making empiric decisions because there are no data to guide specific treatment decisions," Flaig says.

The goal of the current clinical trial was to provide these data. First, participants were randomized to receive either GC or MVAC. Then Flaig and colleagues gathered gene expression signatures for each tumor and asked a simple question using the COXEN approach: Can we predict whether the patient will respond to his or her chemotherapy? Specifically, the doctors including pathologist Scott Lucia, MD, evaluated whether the chemotherapy resulted in "down-staging" of the tumor at the point of surgery, and then whether surgery resulted in removal of all detectable cancer (called "pathologic T0" or a complete pathologic response).

While COXEN was unable to predict whether a patient responded to the MVAC chemotherapy regimen, when MVAC and GC results were pooled, COXEN showed a statistically significant ability to predict which patients responded using the GC biomarker.

"This was not meant to be a definitive trial, but rather a phase II trial that could give us a signal whether COXEN is able to identify responders in a multi-center, prospective trial. I think the GC COXEN biomarker did pretty well, and we look forward to continuing our work in this area," Flaig says.

In addition to generating COXEN signatures, tumors from the trial will be evaluated for DNA, microRNA, SNPs, and circulating tumor cells, potentially allowing for the validation of additional biomarkers to increase the power to predict chemotherapy response.

"When this trial started six or seven years ago, bladder cancer was in a different position - we hadn't had an FDA-approved drug in 30 years. Over the course of this trial, there have been six approved drugs, but none of those drugs are applicable to the neoadjuvant setting. However, with the successful completion of this and other recent bladder cancer trials, there's budding optimism that we can design trials like this to help patients with this common disease," Flaig says.

Flaig also points out that regardless of study results, there still remains compelling data to recommend treatment with cisplatin-based chemotherapy - either GC or MVAC - prior to surgery in the treatment of bladder cancer.

"The bladder cancer research community pulled together to get this trial done," Flaig says. "I'm honored to be part of this group asking and answering questions of essential clinical relevance to our patients."
-end-


University of Colorado Anschutz Medical Campus

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Uncharted
There's so much we've yet to explore–from outer space to the deep ocean to our own brains. This hour, Manoush goes on a journey through those uncharted places, led by TED Science Curator David Biello.
Now Playing: Science for the People

#555 Coronavirus
It's everywhere, and it felt disingenuous for us here at Science for the People to avoid it, so here is our episode on Coronavirus. It's ok to give this one a skip if this isn't what you want to listen to right now. Check out the links below for other great podcasts mentioned in the intro. Host Rachelle Saunders gets us up to date on what the Coronavirus is, how it spreads, and what we know and don't know with Dr Jason Kindrachuk, Assistant Professor in the Department of Medical Microbiology and infectious diseases at the University of Manitoba. And...
Now Playing: Radiolab

Dispatch 1: Numbers
In a recent Radiolab group huddle, with coronavirus unraveling around us, the team found themselves grappling with all the numbers connected to COVID-19. Our new found 6 foot bubbles of personal space. Three percent mortality rate (or 1, or 2, or 4). 7,000 cases (now, much much more). So in the wake of that meeting, we reflect on the onslaught of numbers - what they reveal, and what they hide.  Support Radiolab today at Radiolab.org/donate.